Skip to main content
Top
Published in: Digestive Diseases and Sciences 11/2007

01-11-2007 | Original paper

A Meta-Analysis of Antibiotic Therapy for Active Ulcerative Colitis

Authors: Roja Rahimi, Shekoufeh Nikfar, Ali Rezaie, Mohammad Abdollahi

Published in: Digestive Diseases and Sciences | Issue 11/2007

Login to get access

Abstract

To systematically evaluate the efficacy of antibacterial therapy in ulcerative colitis, we carried out a meta-analysis of controlled clinical trials. Within the time period 1966 through September 2006, PUBMED, EMBASE, and SCOPUS were searched for clinical trial studies that investigated the efficacy of antibiotics in ulcerative colitis. We considered clinical remission as our key outcome of interest. Of 122 studies, 10 randomized placebo-controlled clinical trials matched our criteria and were included in the analysis (530 patients). All the studies used antibiotics as an adjunct therapy to conventional treatment of ulcerative colitis (i.e., corticosteroids and 5-aminosalycilic acid). Pooling of these trials yielded odds ratio (OR) of 2.14 (95% confidence interval [CI], 1.48–3.09; P<0.0001) in favor of antimicrobial therapy. Meta-analysis of short-term trials (5–14 days) showed a higher rate of clinical remission in patients treated with antibiotics (OR, 2.02; 95% CI, 1.36–3). These results suggest that adjunctive antibacterial therapy is effective for induction of clinical remission in ulcerative colitis.
Literature
1.
go back to reference Shen EH, Das KM (2004) Current therapeutic recommendations: infliximab for ulcerative colitis. J Clin Gastroenterol 38:741–745PubMedCrossRef Shen EH, Das KM (2004) Current therapeutic recommendations: infliximab for ulcerative colitis. J Clin Gastroenterol 38:741–745PubMedCrossRef
2.
go back to reference Lichtenstein GR (2001) Is infliximab effective for induction of remission in patients with ulcerative colitis? Inflamm Bowel Dis 7:89–93PubMedCrossRef Lichtenstein GR (2001) Is infliximab effective for induction of remission in patients with ulcerative colitis? Inflamm Bowel Dis 7:89–93PubMedCrossRef
3.
4.
go back to reference Hanauer SB (2006) Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 12:S3–S9PubMedCrossRef Hanauer SB (2006) Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 12:S3–S9PubMedCrossRef
5.
go back to reference Andus T, Gross V (2000) Etiology and pathophysiology of inflammatory bowel disease – environmental factors. Hepatogastroenterology 47:29–43PubMed Andus T, Gross V (2000) Etiology and pathophysiology of inflammatory bowel disease – environmental factors. Hepatogastroenterology 47:29–43PubMed
6.
go back to reference Koutroubakis I, Manousos ON, Meuwissen SG, Pena AS (1996) Environmental risk factors in inflammatory bowel disease. Hepatogastroenterology 43:381–393PubMed Koutroubakis I, Manousos ON, Meuwissen SG, Pena AS (1996) Environmental risk factors in inflammatory bowel disease. Hepatogastroenterology 43:381–393PubMed
7.
go back to reference Sartor RB (1997) Review article: role of the enteric microflora in the pathogenesis of intestinal inflammation and arthritis. Aliment Pharmacol Ther 11 (Suppl 3):17–22, discussion 22–23PubMed Sartor RB (1997) Review article: role of the enteric microflora in the pathogenesis of intestinal inflammation and arthritis. Aliment Pharmacol Ther 11 (Suppl 3):17–22, discussion 22–23PubMed
8.
go back to reference Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, Weber J, Hoffmann U, Schreiber S, Dietel M, Lochs H (2002) Mucosal flora in inflammatory bowel disease. Gastroenterology 122:44–54PubMedCrossRef Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, Weber J, Hoffmann U, Schreiber S, Dietel M, Lochs H (2002) Mucosal flora in inflammatory bowel disease. Gastroenterology 122:44–54PubMedCrossRef
9.
go back to reference Gionchetti P, Rizzello F, Lammers KM, Morselli C, Sollazzi L, Davies S, Tambasco R, Calabrese C, Campieri M (2006) Antibiotics and probiotics in treatment of inflammatory bowel disease. World J Gastroenterol 12:3306–3313PubMed Gionchetti P, Rizzello F, Lammers KM, Morselli C, Sollazzi L, Davies S, Tambasco R, Calabrese C, Campieri M (2006) Antibiotics and probiotics in treatment of inflammatory bowel disease. World J Gastroenterol 12:3306–3313PubMed
10.
go back to reference Nomura T, Ohkusa T, Okayasu I, Yoshida T, Sakamoto M, Hayashi H, Benno Y, Hirai S, Hojo M, Kobayashi O, Terai T, Miwa H, Takei Y, Ogihara T, Sato N (2005) Mucosa-associated bacteria in ulcerative colitis before and after antibiotic combination therapy. Aliment Pharmacol Ther 21:1017–1027PubMedCrossRef Nomura T, Ohkusa T, Okayasu I, Yoshida T, Sakamoto M, Hayashi H, Benno Y, Hirai S, Hojo M, Kobayashi O, Terai T, Miwa H, Takei Y, Ogihara T, Sato N (2005) Mucosa-associated bacteria in ulcerative colitis before and after antibiotic combination therapy. Aliment Pharmacol Ther 21:1017–1027PubMedCrossRef
11.
go back to reference Rizzello F, Gionchetti P, Venturi A, Ferretti M, Peruzzo S, Raspanti X, Picard M, Canova N, Palazzini E, Campieri M (1998) Rifaximin systemic absorption in patients with ulcerative colitis. Eur J Clin Pharmacol 54:91–93PubMedCrossRef Rizzello F, Gionchetti P, Venturi A, Ferretti M, Peruzzo S, Raspanti X, Picard M, Canova N, Palazzini E, Campieri M (1998) Rifaximin systemic absorption in patients with ulcerative colitis. Eur J Clin Pharmacol 54:91–93PubMedCrossRef
12.
go back to reference Casellas F, Borruel N, Papo M, Guarner F, Antolin M, Videla S, Malagelada JR (1998) Antiinflammatory effects of enterically coated amoxicillin-clavulanic acid in active ulcerative colitis. Inflamm Bowel Dis 4:1–5PubMedCrossRef Casellas F, Borruel N, Papo M, Guarner F, Antolin M, Videla S, Malagelada JR (1998) Antiinflammatory effects of enterically coated amoxicillin-clavulanic acid in active ulcerative colitis. Inflamm Bowel Dis 4:1–5PubMedCrossRef
13.
go back to reference Parlak E, Dagli U, Ulker A, Alkim C, Sahin B (2001) Comparison of 5-amino salicylic acid plus glucocorticosteroid with metronidazole and ciprofloxacin in patients with active ulcerative colitis. J Clin Gastroenterol 33:85–86PubMedCrossRef Parlak E, Dagli U, Ulker A, Alkim C, Sahin B (2001) Comparison of 5-amino salicylic acid plus glucocorticosteroid with metronidazole and ciprofloxacin in patients with active ulcerative colitis. J Clin Gastroenterol 33:85–86PubMedCrossRef
14.
go back to reference Gilat T, Leichtman G, Delpre G, Eshchar J, Bar Meir S, Fireman Z (1989) A comparison of metronidazole and sulfasalazine in the maintenance of remission in patients with ulcerative colitis. J Clin Gastroenterol 11:392–395PubMedCrossRef Gilat T, Leichtman G, Delpre G, Eshchar J, Bar Meir S, Fireman Z (1989) A comparison of metronidazole and sulfasalazine in the maintenance of remission in patients with ulcerative colitis. J Clin Gastroenterol 11:392–395PubMedCrossRef
15.
go back to reference Gilat T, Suissa A, Leichtman G, Delpre G, Pavlotzky M, Grossman A, Fireman Z (1987) A comparative study of metronidazole and sulfasalazine in active, not severe, ulcerative colitis. An Israeli multicenter trial. J Clin Gastroenterol 9:415–417PubMedCrossRef Gilat T, Suissa A, Leichtman G, Delpre G, Pavlotzky M, Grossman A, Fireman Z (1987) A comparative study of metronidazole and sulfasalazine in active, not severe, ulcerative colitis. An Israeli multicenter trial. J Clin Gastroenterol 9:415–417PubMedCrossRef
16.
go back to reference Ohkusa T, Nomura T, Terai T, Miwa H, Kobayashi O, Hojo M, Takei Y, Ogihara T, Hirai S, Okayasu I, Sato N (2005) Effectiveness of antibiotic ombination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up. Scand J Gastroenterol 40:1334–1342PubMedCrossRef Ohkusa T, Nomura T, Terai T, Miwa H, Kobayashi O, Hojo M, Takei Y, Ogihara T, Hirai S, Okayasu I, Sato N (2005) Effectiveness of antibiotic ombination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up. Scand J Gastroenterol 40:1334–1342PubMedCrossRef
17.
go back to reference Mantzaris GJ, Archavlis E, Christoforidis P, Kourtessas D, Amberiadis P, Florakis N, Petraki K, Spiliadi C, Triantafyllou G (1997) A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. Am J Gastroenterol 92:454–456PubMed Mantzaris GJ, Archavlis E, Christoforidis P, Kourtessas D, Amberiadis P, Florakis N, Petraki K, Spiliadi C, Triantafyllou G (1997) A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. Am J Gastroenterol 92:454–456PubMed
18.
go back to reference Burke DA, Axon AT, Clayden SA, Dixon MF, Johnston D, Lacey RW (1990) The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther 4:123–129PubMedCrossRef Burke DA, Axon AT, Clayden SA, Dixon MF, Johnston D, Lacey RW (1990) The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther 4:123–129PubMedCrossRef
19.
go back to reference Gionchetti P, Rizzello F, Ferrieri A, Venturi A, Brignola C, Ferretti M, Peruzzo S, Miglioli M, Campieri M (1999) Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid treatment: a double-blind, placebo-controlled trial. Dig Dis Sci 44:1220–1221PubMedCrossRef Gionchetti P, Rizzello F, Ferrieri A, Venturi A, Brignola C, Ferretti M, Peruzzo S, Miglioli M, Campieri M (1999) Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid treatment: a double-blind, placebo-controlled trial. Dig Dis Sci 44:1220–1221PubMedCrossRef
20.
go back to reference Turunen U, Farkkila, Valtonen V (1998) Long-term treatment of ulcerative colitis with ciprofloxacin. Gastroenterology 117:282–283 Turunen U, Farkkila, Valtonen V (1998) Long-term treatment of ulcerative colitis with ciprofloxacin. Gastroenterology 117:282–283
21.
go back to reference Lobo AJ, Burke DA, Sobala GM, Axon AT (1993) Oral tobramycin in ulcerative colitis:effect on maintenance of remission. Aliment Pharmacol Ther 7:155–158PubMedCrossRef Lobo AJ, Burke DA, Sobala GM, Axon AT (1993) Oral tobramycin in ulcerative colitis:effect on maintenance of remission. Aliment Pharmacol Ther 7:155–158PubMedCrossRef
22.
go back to reference Chapman RW, Selby WS, Jewell DP (1986) Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 27:1210–1212PubMedCrossRef Chapman RW, Selby WS, Jewell DP (1986) Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 27:1210–1212PubMedCrossRef
23.
go back to reference Mantzaris GJ, Hatzis A, Kontogiannis P, Triadaphyllou G (1994) Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol 89:43–46PubMed Mantzaris GJ, Hatzis A, Kontogiannis P, Triadaphyllou G (1994) Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol 89:43–46PubMed
24.
go back to reference Mantzaris GJ, Petraki K, Archavlis E, Amberiadis P, Kourtessas D, Christidou A, Triantafyllou G (2001) A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol 36:971–974PubMedCrossRef Mantzaris GJ, Petraki K, Archavlis E, Amberiadis P, Kourtessas D, Christidou A, Triantafyllou G (2001) A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol 36:971–974PubMedCrossRef
25.
go back to reference Dickinson RJ, O’Connor HJ, Pinder I, Hamilton I, Johnston D, Axon AT (1985) Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut 26:1380–1384PubMedCrossRef Dickinson RJ, O’Connor HJ, Pinder I, Hamilton I, Johnston D, Axon AT (1985) Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut 26:1380–1384PubMedCrossRef
26.
go back to reference Jahanshahi G, Motavasel V, Rezaie A, Hashtroudi AA, Daryani NE, Abdollahi M (2004) Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases. Dig Dis Sci 49(11–12):1752–1757PubMedCrossRef Jahanshahi G, Motavasel V, Rezaie A, Hashtroudi AA, Daryani NE, Abdollahi M (2004) Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases. Dig Dis Sci 49(11–12):1752–1757PubMedCrossRef
27.
go back to reference Rezaie A, Parker R, Abdollahi M (2006) Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci (in press) Rezaie A, Parker R, Abdollahi M (2006) Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci (in press)
Metadata
Title
A Meta-Analysis of Antibiotic Therapy for Active Ulcerative Colitis
Authors
Roja Rahimi
Shekoufeh Nikfar
Ali Rezaie
Mohammad Abdollahi
Publication date
01-11-2007
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 11/2007
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-007-9760-1

Other articles of this Issue 11/2007

Digestive Diseases and Sciences 11/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.